Pavlos Msaouel: Our fourth clinical trial designed for Renal Medullary Carcinoma

Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, shared a post on X:

“Excited to activate this week our fourth clinical trial designed for Renal Medullary Carcinoma (RMC).

It will also separately enroll patients with epithelioid sarcoma, another rare but deadly cancer defined by loss of the SMARCB1 tumor suppressor.”

Read more.

“This trial was informed by our discovery that 60-70% of RMC tumors express CA-125 (MUC16) and that a major resistance mechanism to immunotherapy is downregulation of MHC-I which can be bypassed by CD3-targeted bispecifics such as ubamatamab.”

Read more.

“It is also encouraging that there is already anecdotal clinical evidence that this approach can be effective in epithelioid sarcoma.”

Read more.

“As with all our previous trials, we have incorporated correlative and functional analyses to understand why the therapy does or does not work.

This preparedness has allowed us thus far to accelerate discoveries that improve survival outcomes of our patients with RMC.”

“By working together & keep pushing, many histologies, including chromophobe and Translocation Kidney Cancer, will have dedicated clinical trials within the next 2-3 years.

Our commitment to get the average survival of RMC to 5 years before 2030 stands.”

Tittle: Abstract IA028: Renal medullary carcinoma: Discovery and validation of tailored treatment strategies 

Author: Pavlos Msaouel